Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's ...

Novo Nordisk A/S’s failure to meet its own bar for success on a next-generation obesity shot shows the danger of promising too much in the cut-throat market for weight-loss drugs. The Danish ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...

Ozempic maker Novo Nordisk A/S took two large steps toward meeting demand for its blockbuster drugs, committing 8.5 billion kroner ($1.2 billion) to build a new factory in Denmark shortly after it ...

Dec 14 (Reuters) - All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent (CTLT.N), opens new tab had been fulfilled ...

STOCKHOLM/LONDON, Dec 16 (Reuters) - Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs ...

SHANGHAI (Reuters) - As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented remedies are winning approval from some regulators ...

Novo Nordisk's Ozempic Under Scrutiny For Potential Increased Risk Of Rare-Eye Disease New studies link diabetes drug Ozempic to increased risk of NAION, a rare eye condition causing vision loss ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novo Nordisk's stock declined 22% over the past six months, influenced by competitive pressures and supply constraints. Eli Lilly's Zepbound is rapidly gaining market share, challenging Novo's ...